Antibodies

Chapter 3 Antibodies




Summary




Circulating antibodies (also called immunoglobulins) are soluble glycoproteins that recognize and bind antigens, specifically. They are present in serum, tissue fluids or on cell membranes. Their purpose is to help eliminate microorganisms bearing those antigens. Antibodies also function as membrane-bound antigen receptors on B cells, and play key roles in B cell differentiation.


There are five classes of antibody in mammals – IgG, IgA, IgM, IgD, and IgE. In humans, four subclasses of IgG and two of IgA are also defined. Thus, collectively, there are nine isotypes: IgM, IgA1, IgA2, IgG1, IgG2, IgG3, IgG4, IgD, and IgE.


Antibodies have a basic structure of four polypeptide chains – two identical light chains and two identical heavy chains. The N- terminal ~110 amino acid residues of the light and heavy chains are highly variable in sequence; referred to as the variable regions VL and VH, respectively. The unique sequence of a VL/VH pair forms the specific antigen-binding site or paratope. The C-terminal regions of the light and heavy chains form the constant regions (CL and CH, respectively), which determine the effector functions of an antibody.


Antigen-binding sites of antibodies are specific for the three-dimensional shape (conformation) of their target — the antigenic determinant or epitope.


Antibody affinity is a measure of the strength of the interaction between an antibody combining site (paratope) and its epitope. The avidity (or functional affinity) of an antibody depends on its number of binding sites (two for IgG) and its ability to engage multiple epitopes on the antigen – the more epitopes it binds, the greater the avidity.


Receptors for antibody heavy chain constant regions (Fc receptors) are expressed by mononuclear cells, neutrophils, natural killer cells, eosinophils, basophils and mast cells. They interact with the Fc regions of different isotypes of antibody and promote activities such as phagocytosis, tumor cell killing and mast cell degranulation.


A vast repertoire of antigen-binding sites is achieved by random selection and recombination of a limited number of V, D and J gene segments that encode the variable (V) regions (domains). This process is known as V(D)J recombination and generates the primary antibody repertoire.


Repeated rounds of somatic hypermutation and selection act on the primary repertoire to generate a secondary repertoire of antibodies with higher specificity and affinity for the stimulating antigen.


Class switching combines rearranged VDJ genes with different heavy chain constant region genes so that the same antigen receptor can activate a variety of effector functions.



Antibodies recognize and bind antigens


Highly specific recognition of antigen is the hallmark of the adaptive immune response. Two principal molecules are involved in this process:



Structural and functional diversity are characteristic features of these molecules.


Antibody genes have diversified in different species by multiple gene duplications and subsequent divergence. In many species, including man, diversity is further amplified by extensive gene rearrangement and somatic mutation during the lifetime of an individual.




Antibodies are a family of glycoproteins


Five distinct classes of antibody molecule are recognized in most mammals, namely IgG, IgA, IgM, IgD, and IgE. They differ in:



In humans, four subclasses of IgG and two of IgA are defined. Collectively there are nine antibody isotypes: IgM, IgA1, IgA2, IgG1, IgG2, IgG3, IgG4, IgD, and IgE. Each isotype is defined by the amino acid sequence of the heavy chain constant region and encoded by a unique gene. Antibodies present in blood (serum) are polyclonal, i.e. structurally heterogeneous reflecting their ability to recognize and bind different antigens; they are products of different plasma cell clones.




Antibody class and subclass is determined by the structure of the heavy chain


The basic structure of each antibody molecule is a unit consisting of:



In an individual antibody molecule the amino acid sequences of the two light chains are identical, as are the sequences of the two heavy chains. Both light and both heavy chains are folded into a series of discrete domains. The sequence of the constant region of the heavy chain determines the class and subclass, or isotype, of the antibody. The heavy chains are designated:



There are no subclasses of IgM, IgD, or IgE (Fig. 3.3).




Different antibody isotypes activate different effector systems


The human IgG subclasses (IgG1–IgG4), which are are present in serum in the approximate proportions of 66, 23, 7, and 4%, respectively, have arisen after the divergence of evolutionary lines leading to humans and the mouse. Consequently, despite their similar nomenclature there is no direct structural or functional correlation between the four human and mouse IgG molecules identified by the same nomenclature (IgG1, IgG2, etc.).


The relative proportions of IgA1 and IgA2 vary between serum and external secretion, where IgA is present in a secretory form (see Fig. 3.3).









Antibodies have a basic four chain structure


The basic four chain structure and folding of antibody molecules is illustrated for IgG1 (Fig. 3.4).



The light chains (25 kDa) are bound to the heavy chains (55 kDa) by interchain disulfide bridges and multiple non-covalent interactions.


The heavy chains are similarly bound to each other by interchain disulfide bridges and multiple non-covalent interactions.


Each segment of ~110 amino acids folds to form a compact domain, which is stabilized through a multiple non-covalent interaction and a covalent intrachain disulfide bond. Thus:



Each disulfide bond encloses a peptide loop of 60–70 amino acid residues.


There is significant amino acid sequence homology between antibody domains which is reflected in a common conformational motif, referred to as the immunoglobulin fold. This characteristic fold defines the immunoglobulin superfamily members.




Light chains are of two types


Light chain constant domains of most vertebrates have been shown to exist in two structurally distinct types:



These are isotypes, being present in all individuals.


Genetic variants (allotypes) of the κ chains exist in different individuals. There are several possible isotypes of λ chains in humans and the number may vary between individuals.


Either light chain type may combine with any of the heavy chain types, but in any individual antibody molecule both light chains and heavy chains are of the same type.


Amino sequence analysis of monoclonal mouse and human light chains has revealed two structurally distinct regions:



Thus, the light chain variable (VL) and constant (CL) regions were defined (Fig. 3.w1).



Similarly, the ~110 N terminal residues of heavy chains were seen to be unique for each antibody protein analyzed whereas the remaining constant domains were characteristic for each antibody isotype.


The constant domains of the heavy chains are generally designated as CH1, CH2, CH3, and CH4, or according to the isotype of the constant domains.



Hypervariable regions of VH and VL domains form the antigen-combining site


Within the variable regions of both heavy and light chains, some polypeptide segments show exceptional variability and are termed hypervariable regions. These segments are located around amino acid positions 30, 50, and 95 (Fig. 3.w2) and are referred to as Hv1, Hv2, and Hv3 or Lv1, Lv2, and Lv3, respectively.



X-ray crystallographic studies show that the hypervariable regions are intimately involved in antigen binding and hence in creating an interaction site (paratope) that is complementary in shape, charge, and hydrophobicity to the epitope it binds. Consequently the hypervariable regions are also termed the complementarity determining regions (CDR1, CDR2, and CDR3).


The intervening peptide segments are called framework regions (FRs) and determine the fold that ensures the CDRs are in proximity to each other (see Fig. 3.w2).



The overall structure of an antibody depends on its class and subclass


X-ray crystallography has provided structural data on complete IgG molecules (Fig. 3.5). Mobility around the hinge region of IgG allows for the generation of the Y- and T-shaped structures visualized by electron microscopy.



For all antibody isotypes there is pairing between VH/VL and CH1/CL domains through extensive non-covalent interactions to form the antigen binding (Fab) region.


Antigen binding is a common feature for IgG-Fab regions of each of the four human IgG subclasses; however, although there is >95% sequence homology between the IgG-Fc regions each IgG subclass exhibits a unique profile of effector activities.


The hinge regions are structurally distinct and determine the relative mobilities of the IgG-Fab and IgG-Fc moieties within the intact molecule. The equivalent of the IgG hinge region is present in all isotypes, except IgM.


In addition to the pairing of the VL/VH and CL/CH1 domains the CH3 domains of the IgG-Fc are also paired through non-covalent interactions.


The CH2 domains are not paired and, potentially, present a hydrophobic surface to solvent. This unfavorable property is avoided by interactions with a hydrophilic N-linked oligosaccharide moiety.


The N-linked oligosaccharide of the CH2 domain, although accounting for only 2–3% of the mass of the IgG molecule, is crucial to the expression of effector functions. The conformation of the CH2 domain protein moiety, and ultimately the IgG-Fc, results from reciprocal interactions between the CH2 protein and the oligosaccharide. The oligosaccharide exhibits structural heterogeneity and effector functions may be modulated depending on the particular oligosaccharide structure (glycoform) attached.



Assembled IgM molecules have a ‘star’ conformation


IgM is present in human serum as a pentamer of the basic four-chain structure (imagesee Fig. 3.w3). Each heavy chain is comprised of a VH and four CH domains. One advantage of this pentameric structure is that it provides 10 identical binding sites, which can dramatically increase the avidity with which IgM binds its cognate antigen. Given that serum IgM commonly functions to eliminate bacteria containing low affinity, polysaccharide antigens, the increased avidity provided by the pentameric structure provides an important functional advantage.



Covalent disulfide bonds between adjacent CH2 and CH3 domains, the C terminal 18-residue peptide sequence, referred to as the ‘tailpiece’, and J chain link the subunits of the pentamer.


J chain is synthesized within plasma cells, has a mass of ~15 kDa and folds to form an immunoglobulin domain. Each heavy chain bears four N-linked oligosaccharide moieties, however, the oligosaccharides are not integral to the protein structure in the same way as in IgG-Fc. Oligosaccharides present on IgM activate the complement cascade via binding to the mannose binding lectin (see Chapter 4).


In electron micrographs the assembled IgM molecule is seen to have a ‘star’ conformation with a densely packed central region and radiating arms (Fig. 3.6); however, electron micrographs of IgM antibodies binding to poliovirus show molecules adopting a ‘staple’ or ‘crab-like’ configuration (see Fig. 3.6), which suggests that flexion readily occurs between the CH2 and CH3 domains, though this region is not structurally homologous to the IgG hinge. Distortion of this region, referred to as dislocation, results in the ‘staple’ configuration of IgM required to activate complement.




Secretory IgA is a complex of IgA, J chain and secretory component


IgA present in serum is produced by bone marrow plasma cells and secreted as a monomer with the basic four-chain structure. Each heavy chain is comprised of a VH and three CH domains.


The IgA1 and IgA2 subclasses differ substantially in the structure of their hinge regions:



A deficit in the addition of O-linked sugars within the hinge region of IgA1 protein has been linked with the disease IgA nephropathy.


IgA is the predominant antibody isotype in external secretions but is present as a complex secretory form. IgA is secreted by gut localized plasma cells as a dimer in which the heavy chain ‘tailpiece’ is covalently bound to a J chain, through a disulphide bond (see imageFig. 3.w3).


Electron micrographs of IgA dimers show double Y-shaped structures, suggesting that the monomeric subunits are linked end-to-end through the C terminal Cα3 regions (Fig. 3.7).



The dimeric form of IgA binds a poly-Ig receptor (Fig. 3.8) expressed on the basolateral surface of epithelial cells. The complex is internalized, transported to the apical surface where the poly-Ig receptor is cleaved to yield the secretory component (SC) that is released still bound to the IgA dimer. The released secretory form of IgA is relatively resistant to cleavage by enzymes in the gut and is comprised of:







Antibody structural variation


Antibodies show structural variation of three different types – isotypic, allotypic, and idiotypic. The human immunoglobulin isotypes are products of defined immunoglobulin genes encoding the constant regions of heavy and light chains, and the allotypes are polymorphic variants of these genes. The idiotype of an antibody molecule results from antigenic uniqueness reflecting the structural uniqueness of the VH and VL regions (Fig. 3.w4).






Idiotypes result from antigenic uniqueness


The structural uniqueness of antibody variable regions can be reflected in antigenic uniqueness recognized by antisera. However, in addition to antigenic uniqueness, cross-reactivity may be observed for two V regions that are highly homologous. The terms private and public (or cross-reactive and recurrent) idiotypes are used to describe this property. Idiotypes:



Idiotypy (from the Greek ‘idios’, meaning ‘private’) originally referred to the antigenic uniqueness of an individual antibody molecule as recognized by antisera raised in rabbits and mice, by immunization of an individual with a single antibody molecule raised in another member of the same species and allotype. For human IgG proteins heterologous antisera are raised, in rabbits or mice, and absorbed with polyclonal IgG, to absorb cross-reactive antibody. In the modern era monoclonal anti-idiotype antibodies would be generated. They are important reagents when generating assays for quantitative and qualitative analysis of an antibody therapeutic (see Method box 3.1).



Method box 3.1 Recombinant antibodies for human therapy


Recombinant antibody therapeutics (rMAbs) are likely to become the largest family of disease-modifying drugs available to clinicians. Their efficacy results from specificity for the target antigen and biological activities (effector functions) activated by the immune complexes formed. Currently, 26 antibody products are licensed and hundreds are in clinical trials or under development. Initial trials administered mouse monoclonal antibodies specific for human targets and provided ‘proof of principle’.


Q. What problems could you envisage with the use of mouse antibodies to treat diseases in humans?


A. The antibodies might not interact appropriately with human effector molecules, e.g. Fc receptors, complement, etc. In the longer term an individual might mount an immune response against the non-self mouse antibodies.


In practice, patients mounted immune responses against the non-self mouse antibodies and the development of these human anti-mouse antibody responses (HAMA) meant that repeated dosing was not possible.


In response, scientists then produced:


Jun 18, 2016 | Posted by in IMMUNOLOGY | Comments Off on Antibodies

Full access? Get Clinical Tree

Get Clinical Tree app for offline access